Evaluation of PillCam™ Colon 2 in Visualization of the Colon

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Given Imaging Ltd.
ClinicalTrials.gov Identifier:
NCT01087528
First received: March 15, 2010
Last updated: June 10, 2012
Last verified: March 2012

March 15, 2010
June 10, 2012
July 2009
May 2010   (final data collection date for primary outcome measure)
  • Sensitivity of Capsule Endoscopy for Indicated Polyps [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
    Readings of videos from the PillCam COLON were performed by trained physicians who identified polyps (types and sizes). Sensitivity was calculated as the percentage of participants who had positive findings on capsule endoscopy (of a specified category) among those participants who had positive findings on colonoscopy of the same category .The false negative rate is equal to 1 - sensitivity and indicated the percentage of polyps missed by capsule endoscopy.
  • Specificity of Capsule Endoscopy for Indicated Polyps [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
    Readings of videos from the PillCam COLON were performed by trained physicians who identified polyps (types and sizes). Specificity was calculated as the percentage of participants who had negative findings on capsule endoscopy (of a specified category) among participants with negative colonoscopy findings of the same category (reported in Outcome Measure 1). This corresponds to 1 - the false positive rate.
Accuracy parameters of PillCam™ COLON 2 in detecting patients with colonic polyps ≥ 6mm and ≥ 10 mm as compared to conventional colonoscopy [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01087528 on ClinicalTrials.gov Archive Site
Percent of Participants With Scoring Index 3 or 4 [ Time Frame: within 7 days ] [ Designated as safety issue: No ]

Overall colon cleanliness was judged for capsule endoscopy and colonoscopy on a four-point grading index scale as follows:

  1. poor cleansing level (Large amount of fecal residue.)
  2. fair cleansing level (Enough feces or dark fluid present to preclude a completely reliable examination.)
  3. good cleansing level (Small amount of feces or dark fluid, but not enough to interfere with examination.)
  4. excellent cleansing level (No more than small bits of adherent feces.)
  • Diagnostic yield of PillCam™ COLON 2 in detecting colonic lesions as compared to conventional colonoscopy [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Assessment of colon cleansing level at different colon segments for PillCam and Colonoscopy [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Distribution of capsule excretion time up to 10 hours post ingestion based on Rapid videos [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Capsule transit time within stomach, small bowel and colon based on Rapid videos [ Time Frame: within 7 days ] [ Designated as safety issue: No ]
  • Prevalence of polyps at different size categories and locations as detected by capsule and by conventional colonoscopy [ Time Frame: Within 7 days ] [ Designated as safety issue: No ]
  • RAPID reading time Number, type and severity of adverse events [ Time Frame: with in 7 days ] [ Designated as safety issue: No ]
  • Number, type and severity of adverse events [ Time Frame: Within 7 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Evaluation of PillCam™ Colon 2 in Visualization of the Colon
Evaluation of PillCam™ Colon 2 in Visualization of the Colon

To evaluate the performance of PillCam COLON 2 in regards to detection of patients with polyps where colonoscopy is considered as the gold standard reference.

Standard evaluation of subjects with suspected colon diseases includes endoscopic imaging by colonoscopy and radiology testing such as: air-contrast barium enema, abdominal/pelvic CT, or virtual colonoscopy.

The Given® Diagnostic System offers an alternative approach for endoscopic visualization of the colon. Advantages of the Given® Diagnostic System include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the Given® Diagnostic System may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon and comply with colorectal cancer screening recommendations.

The PillCam™ SB capsule (formerly M2A® Capsule) that was cleared by the FDA- in August 2001 for small bowel evaluation has been ingested to date by more than 1,000,000 people worldwide and is well accepted by patients and physicians as well as the professional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. This is expected to improve the capability of the Given® Diagnostic System to detect colonic pathologies and to serve as a diagnostic and screening tool for colonic disease. To date, several clinical studies have been conducted with Given® Diagnostic System and the PillCam™ Colon 1 capsule A pilot multicenter study is currently being conducted with a new Given® Diagnostic System and an advanced generation of the the PillCam™ Colon capsule - PillCam™ Colon 2. Capsule. The new development of Given® Diagnostic System and PillCam™ Colon 2 capsule is primarily aimed to increase sensitivity and specificity for polyp detection.

Further details of the Given® Diagnostic System and PillCam™ Colon 2 capsule can be found in the device description section.

This study is designed to evaluate the performance of the new version of Given® Diagnostic System and PillCam™ Colon 2 capsule in detecting patients with polyps and other colonic lesions as compared to conventional colonoscopy.

Interventional
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Colonic Diseases
  • Bowel Diseases
Device: PillCam™ (Capsule Endoscopy) Colon 2 capsule
Medical Device
Experimental: 1
Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
Intervention: Device: PillCam™ (Capsule Endoscopy) Colon 2 capsule
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
51
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Subject is between the ages of 18-70
  • Subject was referred to colonoscopy for at least one of the following reasons:

    • Colorectal cancer screening for age ≥60
    • Clinical symptoms such as: rectal bleeding, hematochezia, melena, positive FOBT, recent change of bowel habits for age ≥50
    • Positive findings in the colon (e.g. Polyp ≥10mm)
    • Personal history of significant polyps( ≥6mm )that were removed at least 3 years ago (3 years and above)

Exclusion criteria

  • Age > 70 years
  • Subject has dysphagia or any swallowing disorder
  • Subject has congestive heart failure
  • Subject has known renal disease
  • Subject is not eligible for colon preparation due to the presence of underlying conditions based on the clinical judgment of the investigator
  • Subject has any allergy or other known contraindication to the medications used in the study
  • Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator
  • Subject has a cardiac pacemaker or other implanted electro medical device.
  • Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
  • Subject with any condition believed to have an increased risk for capsule retention such as Crohn's disease, intestinal tumors, radiation enteritis, incomplete colonoscopies due to obstructions or NSAID enteropathy,
  • Subject with gastrointestinal motility disorders
  • Subject has known delayed gastric emptying
  • Subject has any condition, which precludes compliance with study and/or device instructions.
  • Women who are either pregnant at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
  • Subject suffers from life threatening conditions
  • Subject currently participating in another clinical study
  • Age>70
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01087528
MA-202
No
Given Imaging Ltd.
Given Imaging Ltd.
Not Provided
Principal Investigator: Douglas Rex, Dr. Division of Gastroenterology, Indiana University Medical Center
Given Imaging Ltd.
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP